跳至主要内容
临床试验/EUCTR2006-006231-49-DE
EUCTR2006-006231-49-DE进行中(未招募)1 期

Ranibizumab in choroidal neovascularization (CNV) due to Pseudoxanthoma elasticum (PXE, Groenblad-Strandberg Syndrome) - PXE-CNV 06

Department of Ophthalmology, Bonn University0 个研究点目标入组 10 人开始时间: 2007年3月6日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 18 – 65 yrs. of age.
  • PXE-diagnosis ascertained by genetic analysis.
  • Angiographically diagnosed CNV in the study eye.
  • Written informed consent.
  • Best corrected visual acuity: 20/200 – 20/32 in the study eye.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Patients with other retinal diseases including diseases of the retinal vessels or diabetic retinopathy.
  • Ocular surgery mess than three months prior to the commencment of the trial.
  • History of a not well meneged glaucoma.
  • Active intraocular inflammation or inflammation of the ocular adnexa.
  • Subfoveal fibrosis in the study eye.
  • Inability, to comply with the study protocol.
  • Major surgical interventions less than 1 month prior to the commencment of the trial.
  • Known allergy to humanized antibodies.
  • History of clinically significant cardiovascular or cerebrovascular disease less than 6 months before commencment of the trial

研究者

发起方
Department of Ophthalmology, Bonn University

相似试验